Text Size

Brain-derived Neurotrophic Factor Participates in Visceral Hyperalgesia in Irritable Bowel Syndrome (IBS) Patients

This study is enrolling participants by invitation only.
Sponsor:
Information provided by:
Shandong University
ClinicalTrials.gov Identifier:
NCT00925223
First received: June 18, 2009
Last updated: October 13, 2009
Last verified: October 2009
History of Changes
  Purpose

Brain-derived neurotrophic factor (BDNF), originally known to be a member of the nerve growth factor family, has aroused attention as a modulator in visceral hyperalgesia recently. Visceral hypersensitivity is recognized as a clinical hallmark in IBS patients. So in this study, the investigators will focus on the role of BDNF in colonic hyperalgesia in IBS patients.


Condition
Irritable Bowel Syndrome

Study Type: Observational
Study Design: Observational Model: Case Control
Official Title: Study of Brain-derived Neurotrophic Factor in Visceral Hyperalgesia in IBS Patients

Resource links provided by NLM:

MedlinePlus related topics: Allergy
U.S. FDA Resources

Further study details as provided by Shandong University:

Biospecimen Retention:   Samples With DNA

two mucosal biospecimens will be obtained from the rectosigmoid junction from each patient.


Estimated Enrollment: 30
Study Start Date: June 2009
Estimated Study Completion Date: November 2009
Estimated Primary Completion Date: August 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts
irritable bowel syndrome
patients with diarrhea-predominant IBS will be enrolled in this group.
control group
patients with colon cancer or colon polyp will be enrolled as control group.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population

Irritable bowel syndrome (IBS) is a common functional gastrointestinal disorder characterized by recurrent abdominal pain or discomfort associated with altered bowel habits in the absence of structural and biochemical abnormalities.

Criteria

Inclusion Criteria:

  • Patients diagnosed with irritable bowel syndrome.

Exclusion Criteria:

  • Patients have similar clinical symptoms as IBS, yet there is morphologic changes in the intestine.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00925223

Sponsors and Collaborators
Shandong University
Investigators
Study Director: Yanqing Li, PhD. MD. Department of Gastroenterology, Qilu Hospital, Shandong University
  More Information

No publications provided

Responsible Party: Yanqing Li, Qilu hospital of Shandong University
ClinicalTrials.gov Identifier: NCT00925223     History of Changes
Other Study ID Numbers: 2009SDU-QILU-G02, NSFC30570831
Study First Received: June 18, 2009
Last Updated: October 13, 2009
Health Authority: China: Ethics Committee

Keywords provided by Shandong University:
IBS
BDNf
visceral hypersensitivity

Additional relevant MeSH terms:
Hyperalgesia
Irritable Bowel Syndrome
Somatosensory Disorders
Sensation Disorders
Neurologic Manifestations
Nervous System Diseases
 Signs and Symptoms
Colonic Diseases, Functional
Colonic Diseases
Intestinal Diseases
Gastrointestinal Diseases
Digestive System Diseases

ClinicalTrials.gov processed this record on May 19, 2013